Literature DB >> 10856299

Mutation of conserved aspartates affects maturation of both aspartate mutant and endogenous presenilin 1 and presenilin 2 complexes.

G Yu1, F Chen, M Nishimura, H Steiner, A Tandon, T Kawarai, S Arawaka, A Supala, Y Q Song, E Rogaeva, E Holmes, D M Zhang, P Milman, P E Fraser, C Haass, P S George-Hyslop.   

Abstract

Presenilin (PS1 and PS2) holoproteins are transiently incorporated into low molecular weight (MW) complexes. During subsequent incorporation into a higher MW complex, they undergo endoproteolysis to generate stable N- and C-terminal fragments. Mutation of either of two conserved aspartate residues in transmembrane domains inhibits both presenilin-endoproteolysis and the proteolytic processing of beta-amyloid precursor protein and Notch. We show that although PS1/PS2 endoproteolysis is not required for inclusion into the higher MW N- and C-terminal fragment-containing complex, aspartate mutant holoprotein presenilins are not incorporated into the high MW complexes. Aspartate mutant presenilin holoproteins also preclude entry of endogenous wild type PS1/PS2 into the high MW complexes but do not affect the incorporation of wild type holoproteins into lower MW holoprotein complexes. These data suggest that the loss of function effects of the aspartate mutants result in altered PS complex maturation and argue that the functional presenilin moieties are contained in the high molecular weight complexes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856299     DOI: 10.1074/jbc.M002982200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Metabolism of presenilins.

Authors:  G Thinakaran
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 2.  Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.

Authors:  Daniel R Dries; Gang Yu
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

Review 3.  Closing in on the amyloid cascade: recent insights into the cell biology of Alzheimer's disease.

Authors:  J T Huse; R W Doms
Journal:  Mol Neurobiol       Date:  2000 Aug-Dec       Impact factor: 5.590

4.  Spatial segregation of gamma-secretase and substrates in distinct membrane domains.

Authors:  Kulandaivelu S Vetrivel; Haipeng Cheng; Seong-Hun Kim; Ying Chen; Natalie Y Barnes; Angèle T Parent; Sangram S Sisodia; Gopal Thinakaran
Journal:  J Biol Chem       Date:  2005-05-10       Impact factor: 5.157

Review 5.  Amyloid metabolism and secretases in Alzheimer's disease.

Authors:  W Xia
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

Review 6.  Presenilin transgenic mice as models of Alzheimer's disease.

Authors:  Gregory A Elder; Miguel A Gama Sosa; Rita De Gasperi; Dara L Dickstein; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2009-11-18       Impact factor: 3.270

7.  Presenilins regulate neurotrypsin gene expression and neurotrypsin-dependent agrin cleavage via cyclic AMP response element-binding protein (CREB) modulation.

Authors:  Angels Almenar-Queralt; Sonia N Kim; Christopher Benner; Cheryl M Herrera; David E Kang; Ivan Garcia-Bassets; Lawrence S B Goldstein
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

8.  Glu-333 of nicastrin directly participates in gamma-secretase activity.

Authors:  Daniel R Dries; Sanjiv Shah; Yu-Hong Han; Cong Yu; Sophie Yu; Mark S Shearman; Gang Yu
Journal:  J Biol Chem       Date:  2009-09-03       Impact factor: 5.157

Review 9.  The presenilins.

Authors:  Anurag Tandon; Paul Fraser
Journal:  Genome Biol       Date:  2002-10-23       Impact factor: 13.583

10.  Physiologically generated presenilin 1 lacking exon 8 fails to rescue brain PS1-/- phenotype and forms complexes with wildtype PS1 and nicastrin.

Authors:  Hannah Brautigam; Cesar L Moreno; John W Steele; Alexey Bogush; Dara L Dickstein; John B J Kwok; Peter R Schofield; Gopal Thinakaran; Paul M Mathews; Patrick R Hof; Sam Gandy; Michelle E Ehrlich
Journal:  Sci Rep       Date:  2015-11-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.